<DOC>
	<DOCNO>NCT01159236</DOCNO>
	<brief_summary>The goal clinical research study learn use `` gene signature '' effective way decide best treatment breast cancer patient . Gene signature may able help researcher predict respond chemotherapy give surgery .</brief_summary>
	<brief_title>Molecular Triaging Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description>At time , treatment stage I-III breast cancer patient high risk cancer return surgery chemotherapy . If cancer positive estrogen hormone receptor , patient also endocrine therapy . The common standard chemotherapy treatment regimens breast cancer M. D. Anderson paclitaxel ( T ) , follow treatment fluorouracil ( F ) , doxorubicin ( A ) epirubicin ( E ) , cyclophosphamide ( C ) . These chemotherapy combination know T/FAC T/FEC . However , patient respond treatment , researcher M. D. Anderson develop test predict much person 's breast cancer might respond T/FAC T/FEC chemotherapy . Fine needle aspiration ( FNA ) tumor collect numbing skin breast local anesthesia , gene within FNA sample measure calculate result treatment prediction test treatment select . In research study , gene-based test help select treatment base prediction response chemotherapy , measure tumor response surgery treatment . Study Drugs : T/FAC T/FEC design damage DNA ( genetic material cell ) , may cause cancer cell die . Bevacizumab design block growth blood vessel supply nutrient necessary tumor growth . This may prevent slow growth cancer cell make susceptible chemotherapy . Tumor Biopsies : If find eligible take part study , 3-4 fine needle biopsy tumor collect . The skin tumor breast tissue surround tumor numb use local anesthesia . To perform fine needle aspiration biopsy , tumor cell withdraw tumor use thin needle alone , use syringe . These biopsy use measure different gene predict cancer may respond different treatment . Based information gene measurement , computer model predict cancer highly sensitive chemotherapy likely shrink great extent disappear completely due chemotherapy . This response prediction do separately estrogen receptor-positive estrogen receptor-negative cancer . Study Groups : If biopsy show cancer may respond well standard T/FAC T/FEC chemotherapy , receive chemotherapy surgery ( Group 1 ) . If biopsy show cancer may respond well standard T/FAC T/FEC chemotherapy , randomly assign ( roll dice ) 1 2 group . - If Group 2 , receive T/FAC T/FEC chemotherapy surgery . One ( 1 ) 3 participant whose cancer may respond well assign group . - If Group 3 , receive T/FAC T/FEC chemotherapy combine bevacizumab surgery . Two ( 2 ) 3 participant whose cancer may respond well assign group . Your doctor decide receive T/FAC T/FEC . Study Drug Administration : Groups 1 2 : Once week Weeks 1-12 , receive paclitaxel vein 1-2 hour . Once every 3 week Weeks 13-24 , receive T/FAC T/FEC vein 3-4 hour . This chemotherapy treatment consider routine standard care may receive treatment close home outside M. D. Anderson . After chemotherapy , surgery M. D. Anderson remove cancer . Group 3 : Once week Weeks 1-12 , receive paclitaxel vein 1-2 hour . Once every 2 week Weeks 1-18 , receive bevacizumab vein 1-2 hour . If doctor think necessary , base heart relate test result , may receive bevacizumab Weeks 1-12 . Once every 3 week Weeks 13-24 , receive T/FAC T/FEC vein 4 hour . You must receive chemotherapy M. D. Anderson group . After chemotherapy , surgery M. D. Anderson remove cancer . Study Visits : All participant routine visit M. D. Anderson least every 12 week chemotherapy . Your doctor determine test procedure perform . If assign Group 3 , also follow additional procedure . - You urine analysis within 1 month start therapy . - You echocardiogram check heart 's health within 3 month begin treatment . Length Study : You may receive chemotherapy 6 month . Once surgery perform , participation study complete . Your doctor decide together treatment need surgery . This investigational study . The biopsy test predict response chemotherapy FDA approve commercially available . Its use study investigational . The chemotherapy surgery standard care patient breast cancer . The addition bevacizumab treatment also investigational . Up 303 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Patients 18 year age old histologically confirm HER2normal ( define fluorescence situ hybridization , FISH &lt; 2.2 immunohistochemistry , IHC &lt; 3+ FISH result available ) invasive carcinoma breast systemic adjuvant therapy clinically indicate . 2 . Patients must intact cancer breast intact regional lymph node ( diagnostic core needle fine needle biopsy allow ) . 3 . Routine estrogen , progesterone HER2 receptor determination must perform start therapy . 4 . Patients prior history breast cancer eligible . 5 . Patients bilateral breast cancer eligible . 6 . Women childbearing potential must negative serum pregnancy test within 2 week start chemotherapy . Patients must agree barrier contraception ( condom ) study . 7 . Patients must agree undergo pretreatment needle biopsy primary tumor breast molecular profiling . 8 . Patients must agree undergo surgery MDACC assign bevacizumab contain chemotherapy must administer MDACC . 1 . Patients anthracycline paclitaxel chemotherapy contraindicate , include : uncompensated congestive heart failure , myocardial infarction within past 12 month , preexist peripheral neuropathy &gt; grade 2 , prior doxorubicin therapy &gt; cumulative dose 240 mg/m^2 2 . Women lumpectomy surgical partial excisional biopsy cancer , sentinel lymph node biopsy positive node , start preoperative therapy . 3 . Exclusion criterion bevacizumab therapy ; inadequately control hypertension ( define systolic blood pressure &gt; /= 140 mmHg and/or diastolic blood pressure &gt; /= 90 mmHg ) . 4 . Exclusion criterion bevacizumab therapy , prior history hypertensive crisis hypertensive encephalopathy , stroke transient ischemic attack . 5 . Exclusion criterion bevacizumab therapy , history myocardial infarction , unstable angina congestive heart failure within 12 month prior start therapy . 6 . Exclusion criterion bevacizumab therapy , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis within 6 month prior start therapy . 7 . Exclusion criterion bevacizumab therapy , history hemoptysis ( 1/2 teaspoon bright red blood per episode ) within 1 month prior start therapy evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 8 . Exclusion criterion bevacizumab therapy . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior start therapy core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior start therapy . 9 . Exclusion criterion bevacizumab therapy , history abdominal fistula gastrointestinal perforation within 6 month prior start therapy . 10 . Exclusion criterion bevacizumab therapy , serious , nonhealing wound fracture active ulcer . 11 . Proteinuria within 1 month start therapy demonstrate either ( ) Urine protein : creatinine ( UPC ) ratio &gt; /= 1.0 ( b ) proteinuria &gt; /= 2+ urine dipstick test . Patients discover &gt; /=2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate &lt; /= 1g protein 24 hour eligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Gene signature</keyword>
	<keyword>HER-2 normal stage I-III breast cancer</keyword>
	<keyword>Estrogen Receptor</keyword>
	<keyword>ER-positive</keyword>
	<keyword>ER-negative</keyword>
	<keyword>RCB category II-III</keyword>
	<keyword>Neoadjuvant Chemotherapy</keyword>
	<keyword>adjuvant systemic therapy</keyword>
	<keyword>molecular testing</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>5-fluorouracil</keyword>
	<keyword>5-FU</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Ellence</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal</keyword>
	<keyword>rhu-MAb-VEGF</keyword>
</DOC>